{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-uk-specific-archiving-and-retention-conditions”
},
“headline”: “SOP for UK-Specific Archiving and Retention Conditions”,
“description”: “This SOP provides detailed procedures for archiving and retention of clinical trial records in the United Kingdom. It ensures compliance with MHRA and GCP requirements, addressing both paper and electronic records, environmental controls, access restrictions, and timelines specific to UK regulations.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-27”,
“dateModified”: “2025-08-27”
}

Standard Operating Procedure for UK-Specific Archiving and Retention Conditions

Purpose

The purpose of this SOP is to define the requirements and detailed procedures for archiving and retention of clinical trial records in the United Kingdom. It ensures compliance with the Medicines and Healthcare products Regulatory Agency (MHRA), UK-GCP, and Data Protection Act (DPA 2018), with emphasis on maintaining data integrity, subject confidentiality, and readiness for regulatory inspection. This SOP also aligns with ICH E6(R2) and reflects UK-specific post-Brexit obligations for record retention.

Scope

This SOP applies to sponsors, CROs, investigators, archivists, data managers, IT administrators, and QA personnel involved in managing trial records. It covers both electronic and paper documents, including Trial Master File (TMF), Investigator Site File (ISF), source documents, informed consent forms, pharmacovigilance records, investigational product documentation, and all data required for MHRA inspection and global regulatory submissions. It also includes guidance on environmental controls for storage facilities, electronic archiving security, and destruction protocols specific to the UK.

Responsibilities

• Sponsor: Ensures long-term archiving of trial documents and sets retention timelines according to MHRA guidance.
• CRO: Implements sponsor-defined archiving processes and provides evidence of compliance.
• Investigator: Retains site-specific essential documents until sponsor confirmation of archive release.
• QA: Audits archiving and retention practices, ensuring facilities and procedures meet MHRA standards.
• IT/Archivist: Maintains secure electronic archives with validated systems, access controls, and disaster recovery plans.

Accountability

The Sponsor’s Head of Clinical Operations is accountable for ensuring that trial records are archived and retained in compliance with MHRA requirements and are accessible for inspection at any time during the mandated retention period.

Procedure

1. Identification of Records for Archiving
1.1 Compile a list of essential documents per ICH GCP Section 8, including TMF, ISF, monitoring visit reports, CRFs, source documents, and safety reports.
1.2 Ensure all records are complete, signed, and dated before transfer to archives.
1.3 Prepare an Archiving Checklist (Annexure-1) to confirm completeness.

2. Retention Timelines (UK Specific)
2.1 Retain trial records for a minimum of 25 years or longer as required by MHRA.
2.2 Retain informed consent forms and subject data in accordance with UK-GDPR and DPA 2018 obligations.
2.3 For pediatric and gene therapy trials, retain records for the subject’s lifetime plus defined regulatory years, as required.
2.4 Record retention decisions in Retention Log (Annexure-2).

3. Storage and Environmental Controls
3.1 Store paper records in fireproof, pest-controlled, temperature- and humidity-monitored facilities.
3.2 Validate electronic archives with audit trails, encryption, and access logs.
3.3 Ensure offsite backup storage is available for redundancy.
3.4 Maintain an Environmental Monitoring Log (Annexure-3).

4. Security and Access Controls
4.1 Limit archive access to authorized personnel only.
4.2 Implement dual authentication for electronic archive access.
4.3 Maintain Archive Access Log (Annexure-4).

5. Document Transfer and Archival Process
5.1 Prepare Transfer Forms with document inventory and unique identifiers.
5.2 Investigator transfers ISF documents to sponsor only after closeout confirmation.
5.3 Sponsor confirms receipt and logs in Archival Receipt Log (Annexure-5).
5.4 Archive all correspondence, approvals, reports, and raw data relevant to UK submissions.

6. Electronic Archiving Validation
6.1 Validate e-archive systems per MHRA and FDA 21 CFR Part 11 equivalence.
6.2 Ensure system provides secure access, version control, and unalterable audit trails.
6.3 Conduct periodic system validation checks and document in e-Archive Validation Log (Annexure-6).

7. Inspection Readiness
7.1 Archive must be inspection-ready, with quick retrieval of documents.
7.2 Perform quarterly mock retrievals and document in Inspection Readiness Log (Annexure-7).

8. Record Destruction
8.1 Records may only be destroyed after expiration of MHRA-mandated retention timelines and sponsor authorization.
8.2 Use certified destruction services with documented proof of destruction.
8.3 Document in Record Destruction Log (Annexure-8).

9. Cross-Border Considerations
9.1 If documents are shared with non-UK authorities, ensure compliance with UK-GDPR transfer mechanisms.
9.2 Maintain logs of all cross-border transfers in Regulatory Transfer Log (Annexure-9).

10. Training and Oversight
10.1 All staff handling archiving must undergo training in MHRA and GCP-specific requirements.
10.2 Maintain training records in Training Log (Annexure-10).

Abbreviations

• SOP: Standard Operating Procedure
• MHRA: Medicines and Healthcare products Regulatory Agency
• TMF: Trial Master File
• ISF: Investigator Site File
• QA: Quality Assurance
• eTMF: Electronic Trial Master File
• DPA: Data Protection Act 2018
• UK-GDPR: UK General Data Protection Regulation

Documents

1. Archiving Checklist (Annexure-1)
2. Retention Log (Annexure-2)
3. Environmental Monitoring Log (Annexure-3)
4. Archive Access Log (Annexure-4)
5. Archival Receipt Log (Annexure-5)
6. e-Archive Validation Log (Annexure-6)
7. Inspection Readiness Log (Annexure-7)
8. Record Destruction Log (Annexure-8)
9. Regulatory Transfer Log (Annexure-9)
10. Training Log (Annexure-10)

References

• MHRA Guidance – Managing Clinical Trial Authorisations
• ICH GCP Guidelines
• UK Data Protection Act 2018

Version: 1.0

Approval Section

Annexures

Annexure-1: Archiving Checklist

Annexure-2: Retention Log

Annexure-3: Environmental Monitoring Log

Annexure-4: Archive Access Log

Annexure-5: Archival Receipt Log

Annexure-6: e-Archive Validation Log

Annexure-7: Inspection Readiness Log

Annexure-8: Record Destruction Log

Annexure-9: Regulatory Transfer Log

Annexure-10: Training Log

Revision History

For more SOPs visit: Pharma SOP